Stanley Laman Group Ltd. Sells 4,100 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Stanley Laman Group Ltd. reduced its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 6.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 61,236 shares of the medical equipment provider's stock after selling 4,100 shares during the quarter. Stanley Laman Group Ltd. owned approximately 0.09% of Lantheus worth $5,478,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of LNTH. Wilmington Savings Fund Society FSB acquired a new stake in shares of Lantheus during the 3rd quarter valued at approximately $25,000. Signaturefd LLC raised its holdings in shares of Lantheus by 40.5% during the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider's stock worth $35,000 after purchasing an additional 92 shares during the period. GAMMA Investing LLC lifted its position in shares of Lantheus by 45.5% in the 3rd quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider's stock worth $51,000 after buying an additional 146 shares during the last quarter. UMB Bank n.a. boosted its holdings in shares of Lantheus by 31.5% in the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock valued at $50,000 after buying an additional 134 shares during the period. Finally, RiverPark Advisors LLC bought a new stake in shares of Lantheus during the 3rd quarter valued at about $74,000. 99.06% of the stock is owned by institutional investors.

Remove Ads

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on LNTH shares. StockNews.com downgraded shares of Lantheus from a "buy" rating to a "hold" rating in a research report on Thursday, November 21st. Truist Financial reiterated a "buy" rating and set a $120.00 price target (down from $135.00) on shares of Lantheus in a research report on Friday, November 8th. JMP Securities reissued a "market outperform" rating and set a $112.00 target price on shares of Lantheus in a research note on Tuesday, January 14th. Finally, The Goldman Sachs Group began coverage on Lantheus in a research report on Wednesday, December 18th. They issued a "buy" rating and a $143.00 price target for the company. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, Lantheus currently has a consensus rating of "Moderate Buy" and an average target price of $131.86.

Lantheus Stock Performance

Shares of NASDAQ LNTH traded down $2.02 during trading on Monday, reaching $79.94. The company had a trading volume of 737,336 shares, compared to its average volume of 709,331. The stock has a market cap of $5.56 billion, a PE ratio of 13.30 and a beta of 0.44. The business's 50 day moving average price is $91.43 and its 200-day moving average price is $97.66. Lantheus Holdings, Inc. has a 52 week low of $56.06 and a 52 week high of $126.89.

Insider Activity

In related news, Director James H. Thrall sold 1,000 shares of the firm's stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the sale, the director now owns 33,207 shares of the company's stock, valued at approximately $3,146,695.32. This trade represents a 2.92 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 1.50% of the company's stock.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.